Five-day aprepitant versus fosaprepitant in patients receiving cisplatin
the ONA take:
Single administration of fosaprepitant meglumine was no less effective than 5-day administration of aprepitant for preventing acute and delayed nausea and vomiting symptoms occurring after administration of cisplatin-based chemotherapy regimens, a new study published online in the journal Supportive Care in Cancer has shown.
For the study, researchers sought to compare the impact of 5-day aprepitant with single administration of fosaprepitant meglumine, the intravenous formulation of aprepitant, on the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic cisplatin-based chemotherapy.
Researchers enrolled 101 patients who received chemotherapy for esophageal, gastric, head and neck, or lung cancer with a regimen containing cisplatin 60 mg/m2 or higher. Participants were randomly assigned to receive either aprepitant for 5 days or one dose of fosaprepitant meglumine.
Results showed no significant differences in the complete response rate or the complete control rate over the 7-day period following the first cisplatin administration.
Single administration of fosaprepitant meglumine no less effective for preventing acute and delayed nausea and vomiting symptoms.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
- The Bounty of Failure: A Well-Versed Nursing Experience
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|